{"version":"1.0","type":"link","title":"Response to Letter to 'Serum CRP in Durvalumab-Tremelimumab-Treated HCC: Expanding the Inflammatory Narrative'.","author_name":"Hatanaka T 외","author_url":"https://prs-insight.online/author/Hatanaka%20T","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/119182","thumbnail_width":1200,"thumbnail_height":630}